New sedative ciprofol aims to cut heart injury after lung surgery

NCT ID NCT07028593

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether ciprofol, a newer sedative, can reduce heart injury after lung surgery compared to the standard drug propofol. About 1,058 adults aged 45–80 having video-assisted lung surgery will be randomly assigned to receive one of the two drugs during anesthesia. The main goal is to see if ciprofol lowers the rate of heart muscle damage in the days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ciprofol (also known as HSK3486)
What this could lead to: If ciprofol works better than propofol, it could become a safer sedative for surgery, lowering the risk of heart damage after lung operations.
What could go wrong: This is a Phase 4 trial, but it only looks at one type of surgery and one complication. Results may not apply to other surgeries or patients, and ciprofol might not prove superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm mediastinal cancer Thoracic Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOCARDIAL INJURY THORACIC DISEASES THORACOSCOPIC SURGERY

Contacts and locations

Locations

Tongji hospital
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.